Peter J.H. Jones

Peter J.H. Jones


Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Atherosclerosis
Verified
Journal Article
Open access
HGHelena Gylling
Helena Gylling
Jogchum PlatJogchum Plat
Jogchum Plat
STStephen Turley
Stephen Turley
HGHenry Ginsberg
Henry Ginsberg
LELars Ellegård
Lars Ellegård
MCM. John Chapman
M. John Chapman
This EAS Consensus Panel critically appraised evidence relevant to the benefit to risk relationship of functional foods with added plant sterols and/or plant stanols, as components of a healthy lifestyle, to reduce plasma low-density lipoprotein-cholesterol (LDL-C) levels, and thereby lower cardiovascular risk. Plant sterols/stanols (when taken at 2 g/day) cause significant inhibition of cholesterol absorption and lower LDL-C levels by between 8 and 10%. The relative proportions of cholesterol versus sterol/stanol levels are similar in both plasma and tissue, with levels of sterols/stanols being 500-/10,000-fold lower than those of cholesterol, suggesting they are handled similarly to cholesterol in most cells. Despite possible atherogenicity of marked elevations in circulating levels of plant sterols/stanols, protective effects have been observed in some animal models of atherosclerosis. Higher plasma levels of plant sterols/stanols associated with intakes of 2 g/day in man have not been linked to adverse effects on health in long-term human studies. Importantly, at this dose, plant sterol/stanol-mediated LDL-C lowering is additive to that of statins in dyslipidaemic subjects, equivalent to doubling the dose of statin. The reported 6-9% lowering of plasma triglyceride by 2 g/day in hypertriglyceridaemic patients warrants further evaluation. Based on LDL-C lowering and the absence of adverse signals, this EAS Consensus Panel concludes that functional foods with plant sterols/stanols may be considered 1) in individuals with high cholesterol levels at intermediate or low global cardiovascular risk who do not qualify for pharmacotherapy, 2) as an adjunct to pharmacologic therapy in high and very high risk patients who fail to achieve LDL-C targets on statins or are statin- intolerant, 3) and in adults and children (>6 years) with familial hypercholesterolaemia, in line with current guidance. However, it must be acknowledged that there are no randomised, controlled clinical trial data with hard end-points to establish clinical benefit from the use of plant sterols or plant stanols.

1 June 1995 in Life Sciences
Verified
Journal Article
Closed access
WLW.H Ling
W.H Ling
PJPeter J.H. Jones
Peter J.H. Jones

10 February 2011 in Lipids
Verified
Journal Article
Closed access
PDF file
LGLeah G. Gillingham
Leah G. Gillingham
SHSydney Harris‐Janz
Sydney Harris‐Janz
PJPeter J.H. Jones
Peter J.H. Jones

1 August 2011 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
Marie-Pierre St-OngeMarie-Pierre St-Onge
Marie-Pierre St-Onge
ARAmy L Roberts
Amy L Roberts
JCJinya Chen
Jinya Chen
MKMichael Kelleman
Michael Kelleman
MOMajella O'Keeffe
Majella O'Keeffe
PJPeter J.H. Jones
Peter J.H. Jones
Background: Evidence suggests a relation between short sleep duration and obesity.Objective: We assessed energy balance during periods of short and h

3 June 2009 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
TWT A Woyengo
T A Woyengo
VRV R Ramprasath
V R Ramprasath
PJPeter J.H. Jones
Peter J.H. Jones

1 February 1998 in Life Sciences
Verified
Journal Article
Closed access
APAndrea A. Papamandjaris
Andrea A. Papamandjaris
DMDiane E. Macdougall
Diane E. Macdougall
PJPeter J.H. Jones
Peter J.H. Jones